Még nem toboroz
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· 3. fázis· Hansoh BioMedical R&D Company· Forrás
Contact: Ding Ma, PhD
Toboroz
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· 3. fázis· Antengene Biologics Limited· Forrás
Contact: Huiqing Zhang
Toboroz
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT07622186· 2. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Contact: Zhentian Liu (principal investigator)
Toboroz
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· 1. fázis· Shanghai Henlius Biotech· Forrás
Contact: Yinping Zhong
Toboroz
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553· 1/2. fázis· Huahui Health· Forrás
Contact: Xiyu Zhang PM
Toboroz
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· 3. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Contact: Rongfeng Song, Master
Toboroz
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
NCT07416474· 3. fázis· RemeGen Co., Ltd.· Forrás
Contact: Yongfeng Yang
Toboroz
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428· 3. fázis· Hutchmed· Forrás
Contact: Yan Huang
Toboroz
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
NCT07402525· Second Affiliated Hospital, Zhejiang University, School of Medicine· Forrás
Contact: Xiaochang Gong
Toboroz
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT07347600· Hoffmann-La Roche· Forrás
Fut, nem toboroz
The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma
NCT07314255· Jiangxi Provincial Cancer Hospital· Forrás
Toboroz
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· 3. fázis· Zai Lab (Shanghai) Co., Ltd.· Forrás
Toboroz
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065· 2. fázis· Guangzhou Lupeng Pharmaceutical Company LTD.· Forrás
Contact: Wuping Li
Toboroz
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650· 1. fázis· Shanghai Henlius Biotech· Forrás
Contact: Henlius
Toboroz
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813· 2. fázis· Beijing Gene Key Life Technology Co., Ltd· Forrás
Contact: Interventional Department
Még nem toboroz
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960· 3. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Contact: Wuping Li, Doctor
Toboroz
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
NCT07296705· 2. fázis· Fujian Medical University Union Hospital· Forrás
Contact: Xinhua Tu
Fut, nem toboroz
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335· 1. fázis· Shanghai Henlius Biotech· Forrás
Toboroz
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: Zhengkui Sun, Site 1013
Toboroz
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
NCT07169994· 1/2. fázis· MediLink Therapeutics (Suzhou) Co., Ltd.· Forrás
Contact: Study Coordinator
Toboroz
A Study of SKB518 in Patients With Lung Cancer
NCT07019675· 2. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Contact: Hui Luo
Fut, nem toboroz
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· 3. fázis· Amgen· Forrás
Toboroz
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908· 1/2. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: RongFeng Song, Master
Toboroz
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: Zhengkui Sun, Doctor
Toboroz
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
NCT07008976· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Forrás
Contact: Zhengkui Sun, Doctor
Toboroz
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
NCT07327034· 2. fázis· Abbisko Therapeutics Co, Ltd· Forrás
Contact: Xiaoyong Wei
Toboroz
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· 1/2. fázis· BioNTech SE· Forrás
Toboroz
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
NCT06860971· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Zhijun Chen, Master
Fut, nem toboroz
Predictive Value of Albumin - Bilirubin Score and CRP - Albumin - Lymphocyte Index for HCC Prognosis After Radical Resection
NCT06934070· Qiang Xu· Forrás
Toboroz
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT06854445· 2. fázis· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Forrás
Contact: Wuping Li, Doctor
Toboroz
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
NCT06752239· 3. fázis· Jiangxi Provincial Cancer Hospital· Forrás
Contact: Jingao Li, PhD
Fut, nem toboroz
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921· 3. fázis· Jiangsu Simcere Pharmaceutical Co., Ltd.· Forrás
Fut, nem toboroz
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT06616532· 3. fázis· Biotheus Inc.· Forrás
Fut, nem toboroz
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· 3. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Toboroz
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485· 2. fázis· Zhejiang Haichang Biotech Co., Ltd.· Forrás
Contact: Angela Men, MD., Ph.D
Toboroz
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207· 1/2. fázis· Innovent Biologics (Suzhou) Co. Ltd.· Forrás
Contact: Serena Dong
Fut, nem toboroz
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· 3. fázis· Biotheus Inc.· Forrás
Fut, nem toboroz
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· 3. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Fut, nem toboroz
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036· 3. fázis· Amgen· Forrás
Toboroz
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888· 2/3. fázis· Hutchmed· Forrás
Contact: Huiqing Zhang
Toboroz
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06521255· 3. fázis· Beijing InnoCare Pharma Tech Co., Ltd.· Forrás
Contact: Yan Huang
Toboroz
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735· 1. fázis· Qilu Pharmaceutical Co., Ltd.· Forrás
Contact: Shanxian Guo, Professor
Fut, nem toboroz
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· 2/3. fázis· TJ Biopharma Co., Ltd.· Forrás
Toboroz
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Zhenntian Liu, Master
Fut, nem toboroz
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· 3. fázis· Amgen· Forrás
Toboroz
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776· Daiichi Sankyo· Forrás
Contact: Principal Investigator
Toboroz
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· 3. fázis· Daiichi Sankyo· Forrás
Contact: Study Coordinator
Toboroz
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
NCT06010329· 2. fázis· Teligene US· Forrás
Contact: Xiaoyang Xia
Showing 50 of 68.